'Easy to work with' tops CRO benchmarking report

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/3D_generator)
(Image: iStock/3D_generator)
With or without a preferred provider – what do pharma sponsors look for in a contract research organization?

The report, published​ by Industry Standard Research (ISR), surveyed users on their experiences with 37 Phase II/III CROs.

One dynamic we found was ‘easy to work with’ has its highest importance ranking when a company does not have preferred providers​,” Andrew Schafer, president at Industry Standard Research, told Outsourcing-Pharma.com

When a sponsor selects a company as a preferred provider, there are many decision points that can be universally agreed upon and then do not have to be discussed or negotiated at the start of every project​.”

Additionally, when working with a preferred provider​ on a repeat basis, which is often the case, the relationship forms certain efficiencies.

However, as Schafer explained, when there are no preferred providers in place, “details must be hammered out for each project and there may not be a pre-established working relationship​.”

These factors may play large roles in why those with no preferred provider agreements place more importance on being ‘easy to work with​,’” he said.

Other attributes examined included commercial market knowledge, regulatory knowledge, site and investigator networks, innovation, patient recruitment strategies, technology, contingency planning, and data quality.

Notably, “network of sites and investigators​” was cited as important for those respondents who have formal preferred providers but were in a situation in which a vendor was being selected from outside this list.

This may mean when companies with preferred provider lists go away from them that they are looking for service providers who have access to therapeutic areas or geographies their preferred providers do not cover well​,” said Schafer.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us

Products

View more

Webinars